![](/wp-content/uploads/2018/10/e7hfJQyzSZCgo1tsxGc6.png)
$599
Novo 2019 Capital Markets Day Highlights and Analysis
Novo hosted its 2019 Capital Markets Day and provided updates on the strategic direction of the company through 2025 including commercial activities and R&D strategy. Of note, Novo provided clarity on Rybelsus positioning vs. Ozempic and competitor products as well as details on novel drug delivery technologies, including two oral peptide delivery methods being developed at MIT and the semaglutide+AM833 injection device. Below, FENIX provides details and insights from the call.